Axsome Therapeutics Stock Surges on FDA Approval and Positive Earnings Report
Axsome Therapeutics (AXSM) stock surged over 8% following FDA approval for a new indication and a positive first-quarter earnings report. The company's drug, Auvelity, received approval for treating agitation related to dementia in Alzheimer's patients, potentially expanding its market significantly. The stock had already risen over 20% in the previous month.
Tickers: $AXSM
Topics: Axsome Therapeutics Biopharmaceuticals Drug Development FDA Approval Stock Performance